Bioequivalence assessment of generic drugs: An American point of view

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 2, 1996, Pages 159-164

  Patnaik, R ^a   Lesko, L J ^a   Chan, K ^a   Williams, R L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bioavailability; Bioequivalence

Indexed keywords

BIOEQUIVALENCE; CONFERENCE PAPER; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; INDIVIDUALITY; METHODOLOGY; PHARMACOKINETICS; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0030017516     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190265     Document Type: Conference Paper

References (21)

1. United States Federal Register (1977): 42(5), 1624.
2. Drug Price Competition & Patent Term Restoration Act (1984) : Public Law 98-417.
3. Henderson J., Dighe S.V., Williams R.L. (1992) . Subject selection and maintenance in bioequivalence studies. Clin. Res. Practices Drug Regulatory Affairs, 9, 71-88.
4. Dawling S., Crome P. (1989) : Clinical pharmacokinetic considerations in elderly: an update. Clin. Pharmacokinet., 17, 236.
5. Wilson K. (1984) : Sex related differences in drug disposition in man. Clin. Pharmacokinet., 9, 189.
6. Approved Drug Products with Therapeutic Equivalence Evaluation (1995) : United States Government Printing Press. 15th Edn.
7. Schuirmann D. (1987) : A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm., 15, 657.
8. Adams W.P., Singh G.J.P. (1995) : Guidance for topical dermatologic corticosteroids: in vivo bioequivalence. Division of Bioequivalence, OGD, FDA.
9. Adams W.P, Molzoa J.A., Singh G.J.P. (1994) : Interim guidance for documentation of in vivo bioequivalence of albuterol inhalation aerosols (Metered Dose Inhalers). Division of Bioequivalence, OGD, FDA.
10. Nerurkar S.G., Singh H.H. (1993) : Interim guidance: cholestyramine powder in vitro bioequivalence. Division of Bioequivalence, OGD, FDA.
11. Schall R., Luus H.G. (1993) : On population and individual bioequivalence. Stat. Med., 12, 1109-1124.
12. Sheiner L.B. (1992) : Bioequivalence revisited. Stat. Med., 11, 1777-1788.
13. Steinjans V.W., Hauschke D., Jonkman J.H.G. (1992) : Controversies in bioequivalence studies. Clin. Pharmacokinet., 22, 247-253.
14. Hauck W.W., Anderson S.A. (1984) : A new procedure for testing equivalence in two group comparative bioavailability trials, J. Pharmacokinet. Biopharm., 12, 83-89.
15. Anderson S.A., Hauck W.W. (1990) : Consideration of individual bioequivalence. J. Pharmacokinet. Biopharm., 18: 259-273.
16. Chen M.L. (1992) : Alternative approach for the assessment of rate of absorption in bioequivalence studies. Pharm. Res., 9, 1380-1385.
17. max for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol., 29, 394-399.
18. Schall R., Luus H.G. (1991) : Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 153-159.
19. Bois F.Y., Tozer T.N., Hauck W.W., Chen M.L., Patnaik R., Williams R.L. (1994) : Bioequivalence performance of several measures of rate of absorption. Pharm. Res., 11, 966-974.
20. Nerurkar S.G., Dighe S.V., Williams R.L. (1992) : Bioequivalence of racemic drugs. J. Clin. Pharmacol., 32, 935-943.
21. Blume H.H., McGilveray, Midha K.K. (1995) : Bio-international '94. Conference on Bioavailabilily, Bioequivalence and Pharmacokinetic Studies and Pre-Conference Satellite on In Vivo/In Vitro Correlation. Eur. J. Drug Metab. Pharmacokinet., 20, 3-13.